FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for diagnosis of a tumor. Pre-anesthetized animals in the infraorbital sinus are administered with a radiopharmaceutical (RPP) based on technetium-99m labeled doxorubicin at a dose of 20 MBq intravenously. After 30–40 minutes perform a scintigraphic study in the planar mode. Record a scintigram for 5 minutes. With increasing accumulation of RPP in tissues, more than 2 times greater than its accumulation in symmetrically located areas, a tumor is diagnosed.
EFFECT: invention provides increase in accuracy and informativity of diagnostics.
1 cl, 1 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF RADIONUCLIDAL DIAGNOSTICS OF BREAST CANCER | 2017 |
|
RU2682880C1 |
| METHOD FOR RADIONUCLIDE DIAGNOSING OF CEREBRAL TUMORS | 2017 |
|
RU2692451C2 |
| METHOD FOR RADIONUCLIDE DIAGNOSTICS OF LUNG CANCER | 2020 |
|
RU2751103C1 |
| METHOD OF RADIONUCLIDAL DIAGNOSTICS OF LARYNGEAL AND PHARYNGOPHARYNGEAL CANCER | 2017 |
|
RU2679298C1 |
| RADIONUCLIDE DIAGNOSTIC TECHNIQUE FOR BREAST CANCER WITH Her2/neu HYPEREXPRESSION | 2019 |
|
RU2720801C1 |
| COLON CANCER DIAGNOSIS METHOD | 2021 |
|
RU2755010C1 |
| METHOD FOR RADIONUCLIDE DIAGNOSING OPERABLE BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU | 2019 |
|
RU2702294C1 |
| DIAGNOSTIC TECHNIQUE FOR STOMACH CANCER WITH HER2/NEU OVEREXPRESSION | 2020 |
|
RU2739107C1 |
| METHOD FOR EVALUATING NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS WITH HER2/NEU OVEREXPRESSION | 2022 |
|
RU2785387C1 |
| METHOD FOR ASSESSING THE REGIONAL SPREAD OF BREAST CANCER BY SINGLE-PHOTON EMISSION COMPUTER TOMOGRAPHY | 2017 |
|
RU2679302C1 |
